YRDC Mediates the Resistance of Lenvatinib in Hepatocarcinoma Cells via Modulating the Translation of KRAS.

导出 LinkOut

翻译打印收藏纠错

作者： Jun,Guo ^[1] ; Peng,Zhu ^[2] ; Zhi,Ye ^[3] ; Mengke,Wang ^[4] ; Haijun,Yang ^[1] ; Shiqiong,Huang ^[2] ; Yan,Shu ^[3] ; Wei,Zhang ^[4] ; Honghao,Zhou ^[5] ; Qing,Li ^[1]

作者单位： Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China. ^[1] Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, China. ^[2] Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, China. ^[3] National Clinical Research Center for Geriatric Disorders, Changsha, China. ^[4] Department of Anesthesiology, Xiangya Hospital, Central South University, Changsha, China. ^[5] Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland at Baltimore, Baltimore, MD, United States. ^[6]

关键词 HCC KRAS Lenvatinib YRDC t6A modification

DOI 10.3389/fphar.2021.744578

PMID 34658879

发布时间 2021-10-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Frontiers in pharmacology

2021年12卷

744578页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

YRDC Mediates the Resistance of Lenvatinib in Hepatocarcinoma Cells via Modulating the Translation of KRAS.

Frontiers in pharmacology

相似文献

Frontiers in pharmacology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

YRDC Mediates the Resistance of Lenvatinib in Hepatocarcinoma Cells via Modulating the Translation of KRAS.

Frontiers in pharmacology

相似文献

Frontiers in pharmacology

相关期刊

检索历史清除